期刊
MULTIPLE SCLEROSIS AND RELATED DISORDERS
卷 57, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2021.103343
关键词
Multiple sclerosis; Cladribine tablets; COVID-19 vaccination; Serology; SARS-CoV-2
资金
- healthcare business of Merck KGaA, Darmstadt, Germany [MS700568_0167]
- Merck KGaA, Darmstadt, Germany
The study found that multiple sclerosis patients treated with cladribine are able to develop antibody response to the SARS-CoV-2 vaccine. This is reassuring and important for both patients and physicians, and could help in developing consensus guidelines.
Background: multiple sclerosis (MS) patients are treated with immunomodulatory treatments that can influence their ability to develop a protective antibody response to the SARS-CoV-2 vaccine. Vaccine efficacy is important for treatment decision and for patients' reassurance. The main objective is to assess antibody response to SARS-CoV-2 vaccine in MS patients treated with cladribine. Methods: Serology response was tested in 97 participants, 67 MS patients and 30 healthy controls (HCs), using two independent methods, 2-3 weeks following the second dose of the BNT162b2 vaccine. Results: HCs (n = 30) and MS patients treated with cladribine (n = 32) had 100% positive serology response against the SARS-CoV-2 spike protein following the second vaccine dose (mean S1/S2-IgG and RBD-IgG:284.5 +/- 104.9, 13,041 +/- 9411 AU/mL and 226.3 +/- 121.4, 10,554 +/- 11,405 AU/mL respectively). Comparable findings were observed for untreated MS patients, and interferon beta-1a-treated MS patients (mean S1/S2-IgG: 282.1 +/- 100.1, 276.9 +/- 94.31 AU/mL respectively). No correlation was found between lymphocyte counts, treatment duration, or time between cladribine dose and vaccination, and serology response or antibody titers. Conclusion and relevance: Cladribine treated MS patients are able to produce antibodies to the SARS-CoV-2 mRNA vaccine. In the era of the COVID-19 pandemic, it is reassuring and important for both patients and physicians and will allow to develop consensus guidelines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据